Infectious disease research   neurology Research

JN’s research and development organization draws upon expertise in multiple discovery plat­forms.   We have outlined a number of early-stage development that include three novel CNS vaccines and diagnostics to fight Stroke and Alzheimer’s diseases. An anti-TIA/Stroke an oral therapeutic vaccine and point-care settings diagnostics for CNS diseases are in process of human trials. We also have programs progressing through development that seek to expand existing products with newly identified uses and indications. We are hopeful for U.S. approval in 2012 for Meningococcal conjugate vaccine and our human trial outcome will be reviewed at an FDA advisory committee meeting. Our NMDA therapeutics, under investigation  is targeted for regulatory filing in the first half of 2013.

Herpes Clinical studies

Genital herpes Vaccine (GH) human studies:

Type 2 (HSV-2) is a suitable target for a vaccine, despite available antiviral therapies, because the virus causes lifelong infection and significant medical and psychosocial morbidity.

GH non-IND Phase-1 non-IND Study: This study has been initiated in Cambodia using Herpes infected and control subjects.

TIA / Ischemic Stroke Clinical studies

Stroke Vaccine Phase-1 non-IND human study:

This first stage of stroke clinical trials is designed to gain basic safety and pharmacologic information. Single or multiple conservative doses of the drug will be administered to volunteers in South Africa.

  

Over the past 15 years, new  Neurological therapy candidate were placed into development, with 2 advancing to pre-clinical trials. The majority of these have the potential to be first- or best-in-class preventive and therapies for Transient Ischemic Stroke and Alzheimer's .

  JN-International, Inc. USA
View Photo Slideshow

JN's Quality Control & Research Laboratory

CNS R&D - A proof of concept


 

Videos &  PowerPoint

  • TIA and Stroke diagnostics               

  • NMDA Mechanism of Action               

  • NMDA auto-antibodies                       

  • Therapeutic target biomarkers          

  • Therapeutics for Ischemic Stroke      

   

 

         Vaccines & Therapeutics  

 
 

Meningococcal oligo-polysaccharide diphtheria conjugate vaccine for age 2 to 55

 

 NMDA antagonist neurological vaccine
 

 Prophylactic & Therapeutic for HSV          
 

 CNS TB VACCINE     
 

 NS3/NS4 based vaccine                      
 
 nSPA epitope vaccine  
 

© 1998 JN-International, Inc. Oakland, Nebraska 68045, USA . BYLAWS | TERMS OF USE LEGAL DISCLAIMER